Results 161 to 170 of about 51,359 (249)

Homologous recombination pathway alterations in basal-like breast cancer. [PDF]

Front Oncol
Aho S, Guyot B, Maguer-Satta V.
europepmc   +1 more source

Single‐Cell Transcriptomic Identification of Drug‐Tolerant Persister Mechanisms in Capecitabine‐Treated Triple‐Negative Breast Cancer

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. This lack of receptors limits targeted therapies and contributes to high rates of recurrence.
Md Naiyem Islam, Md Kaziul Islam Sarkar Suja, Alif Al Takbir, Md. Kaderi Kibria   +3 more
wiley   +1 more source

Kaiso modulates androgen receptor expression in triple-negative breast cancer. [PDF]

Breast Cancer Res
Ali Fairbairn S, Kim K, Cowan RW, Lessey LR, Fanaian M, Adan H, Golamari S, Rattan R, Daniel JM.   +8 more
europepmc   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, Volume 159, Issue 8, Page 1990-2003, 15 October 2026.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Targeting SIK2 with GRN-300 Potentiates Paclitaxel Efficacy in Triple-Negative Breast Cancer. [PDF]

Cancers (Basel)
Pina MA, Ozyurt R, Mao W, Yang H, Santiago-O'Farrill JM, Lu Z, Bast RC.   +6 more
europepmc   +1 more source

(S)‐Pyrrolo[1,2‐a]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Among 30 synthesized pyrrolo[1,2‐a]pyrazine analogs, compounds B1 and B3 showed strong and selective cytotoxicity toward TNBC cells, inducing apoptosis through Akt suppression and JNK activation. Triple‐negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies.
Narges Hosseininasab, Sou Hyun Kim, Ye‐Mi Kwon, Jungjin Park, Chanhyun Jung, Kwanghee Lee, Beom‐Jun Wi, Su‐Jin Yoo, Soonsil Hyun, Young‐Suk Jung, Jae‐Hwan Kwak   +10 more
wiley   +1 more source

SPDEF downregulation promotes tumor aggressiveness and poor prognosis in triple-negative breast cancer. [PDF]

Transl Cancer Res
Wei C, Liu Q, Wang H, Liu X.
europepmc   +1 more source

Report on the 13th international workshop on the CCN family of genes and inaugural ARBIOCOM conference, Nice, France

Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.
Celebration of the 13th ICCNS meeting joint to the 1st ARBIOCOM Conference held on the site of Nice in December 2025. Abstract The 13th International Workshop on the CCN Family of Genes, held in Nice as part of the inaugural ARBIOCOM World Conference, brought together investigators with diverse research backgrounds, disciplines, and expertise. Building
Bernard Perbal, Ralf Weiskirchen, Annick Perbal, Brahim Chaqour   +3 more
wiley   +1 more source

Distinct Transcriptional and Migratory Programs Are Associated with Vasculogenic Mimicry Heterogeneity in Triple-Negative Breast Cancer. [PDF]

Cancers (Basel)
Madhavan-Kadali S, Cho HM, Sneh T, Bloch N, Rosenblatt JD, Samson AO, Gil-Henn H.   +6 more
europepmc   +1 more source

MUC1 as a Survival Effector of Radiotherapy‐Induced Epithelial Hybrid States in Basal‐Like Breast Cancer

International Journal of Cancer, Volume 159, Issue 5, Page 1296-1310, 1 September 2026.
Basal‐like breast cancer (BLBC) is aggressive and often exhibits inherent or acquired resistance to radiotherapy (RT), a primary treatment option. RT resistance is underpinned by molecular alterations, many of which are poorly understood. Here, RT‐induced transcriptomic changes were analyzed using bulk and spatial sequencing in a BLBC mouse model and ...
Garyfallia Pantelaiou‐Prokaki, Husam Bamahmoud, Nadine S. Georges, Shaishavi Jansari, Annika Jung, Daniela Grimm, Evangelos Prokakis, Fabian Alexander Gayer, Maryam Deldar, Christian Dullin, Julia Gallwas, Florian Wegwitz, Frauke Alves   +12 more
wiley   +1 more source